SEC Form 4 · accession 0001209191-17-049764
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred D Kingsley
Officer — See Remarks · Director
Period of report
Aug 17, 2017
Accepted (ET)
Aug 21, 2017 · 9:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par valueF1,F2 | Aug 17, 2017 | D | 300,000 | $2.81 | D | 5,481,555 | D | |
| Common Shares, no par value | holding | — | — | — | 1,143,346 | I | By Greenbelt Corp. | |
| Common Shares, no par value | holding | — | — | — | 375,351 | I | By Greenway Partners, LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On August 17, 2017, Mr. Kingsley exchanged 300,000 BioTime common shares for 421,500 common shares of AgeX Therapeutics, Inc., a subsidiary of BioTime.
- F2Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
Remarks
Mr. Kingsley is Chairman of certain BioTime subsidiaries.